Genomic characterization of upper tract urothelial carcinoma (UTUC) with or without sarcomatoid differentiation.
Salvador Jaime-Casas(City of Hope), Abhishek Tripathi(City of Hope), Benjamin Mercier(City of Hope), Nicholas Salgia(Roswell Park Comprehensive Cancer Center), Wesley Yip(City of Hope), Xiaochen Li(City of Hope), Alex Chehrazi‐Raffle(City of Hope), Charles B. Nguyen(Michigan Medicine), Sumanta Kumar Pal(City of Hope), Daniela V. Castro(City of Hope), Hedyeh Ebrahimi(Beth Israel Deaconess Medical Center), Koral Shah(City of Hope), Vitor Góes(City of Hope), JoAnn Hsu(City of Hope), Nazli Dizman(The University of Texas MD Anderson Cancer Center), T. Dorff(City of Hope), Regina Barragan-Carrillo(City of Hope), Miguel Zugman(City of Hope)
Cited by 0
Related Papers
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
|Journal for ImmunoTherapy of Cancer|2018|184
Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.
|Journal of Clinical Oncology|2024|9
Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010
|European Urology Oncology|2024|4
Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study.
|Journal of Clinical Oncology|2024|1